|
May 2
|
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
|
|
Apr 30
|
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
|
|
Apr 14
|
10 Micro-Cap Healthcare Stocks Insiders Are Buying
|
|
Apr 9
|
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
|
|
Apr 8
|
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
|
|
Apr 8
|
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
|
|
Dec 20
|
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
|
|
Dec 18
|
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
|
|
Oct 24
|
Palatin Announces Closing of $5 Million Registered Direct Offering
|
|
Oct 23
|
Palatin Announces $5 Million Registered Direct Offering
|
|
Oct 19
|
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
|
|
Oct 18
|
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
|
|
Aug 10
|
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
|
|
Aug 8
|
Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
|
|
Aug 7
|
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®
|
|
Aug 4
|
Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference
|